Features of management of patients with liver diseases in the conditions of the COVID-19 pandemic

Autor:	Yuriy A. Kravchuk
Rok vydání:	2021
Předmět:	medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Pandemic medicine Intensive care medicine business
Zdroj:	Russian Military Medical Academy Reports. 40:57-62
ISSN:	2713-2323 2713-2315
DOI:	10.17816/rmmar76270
Popis:	Liver dysfunction is common with COVID-19 infection, and the prevalence is higher in men as well as in the elderly. Manifestations of liver damage such as high aspartate aminotransferase and alanine aminotransferase activity, increased bilirubin levels, low albumin levels, and prolonged prothrombin time are associated with severe COVID-19 infection. Mortality in patients with diffuse liver diseases without cirrhosis with COVID-19 infection was 12 %, in the presence of liver cirrhosis up to 40%, decompensated liver cirrhosis up to 4363%. The mechanisms of liver damage in COVID-19 include direct hepatotoxicity and indirect liver damage (due to systemic inflammation with impaired immunity, sepsis, hypoxia, ischemia, coagulopathy, endotheliitis, right ventricular failure, worsening of the course of existing liver diseases, drug liver damage). Treatment of patients with diffuse liver diseases includes lifestyle and nutritional modification, the use of hepatoprotective drugs, and means of correcting the intestinal barrier (bibliography: 30 refs).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::308f8ff97d9ce4fb37055241b8109c38 https://doi.org/10.17816/rmmar76270 Zobrazit plný text záznamu